Antibody Drug Conjugates (ADC)

What are antibody drug conjugates (ADCs)?

Antibody Drug Conjugates (ADCs) are a class of targeted cancer therapeutics that combine the tumor-targeting precision of a monoclonal antibody (mAb) with the cell-killing power of a highly potent cytotoxic small molecule, connected by a chemical linker. The concept is elegantly simple: use the antibody as a homing device to deliver a toxic payload directly to tumor cells while sparing normal tissues — the pharmacological equivalent of a precision-guided weapon.

Conventional chemotherapy lacks tumor selectivity — cytotoxic agents distribute throughout the body, damaging healthy tissues and causing the dose-limiting toxicities that constrain their therapeutic window. ADCs address this fundamental limitation by exploiting tumor-associated antigens (TAAs) — proteins that are overexpressed on the surface of cancer cells and minimally present on normal cells — as molecular addresses that direct the delivery of the cytotoxic payload precisely where it is needed.

The ADC field has undergone a dramatic transformation since the first FDA approval of gemtuzumab ozogamicin (Mylotarg) in 2000. The failures of early-generation ADCs — driven by suboptimal linker stability, heterogeneous conjugation, and narrow therapeutic windows — have been systematically addressed through advances in antibody engineering, linker chemistry, payload design, and site-specific conjugation technologies. The result is a new generation of ADCs with dramatically improved efficacy and tolerability profiles that have transformed the treatment landscape for multiple cancer types.

As of 2025, over 12 ADCs have received FDA approval, and more than 100 are in active clinical development across oncology, autoimmune disease, and infectious disease. Antibody drug conjugates represent one of the most active and commercially valuable drug classes in the pharmaceutical industry, with multiple blockbuster approvals and billions of dollars in platform licensing deals in recent years.

The three components of an ADC

Every antibody drug conjugate consists of three precisely engineered components. The performance of an ADC depends on the optimal design of each component individually and their collective behavior as an integrated molecular system.

1. The monoclonal antibody (mAb)

The antibody component provides the tumor-targeting selectivity of an ADC. Most approved ADCs use full-length IgG1 antibodies — which combine high target affinity with favorable pharmacokinetic properties (long half-life, FcRn recycling) and immune effector function (ADCC, CDC). The ideal ADC antibody target antigen satisfies several criteria: high and homogeneous expression on tumor cells; low or absent expression on critical normal tissues; rapid and efficient receptor-mediated internalization upon antibody binding; and lack of circulating antigen (shed antigen can bind and neutralize the ADC before it reaches the tumor). Current ADC programs target antigens across solid tumors and hematologic malignancies including HER2, TROP2, HER3, B7-H4, CD30, CD33, CD22, CD79b, Nectin-4, and many others.

2. The chemical linker

The linker connects the antibody to the payload and controls the timing, location, and selectivity of payload release. Linker design is one of the most critical determinants of ADC safety and efficacy. There are two main linker types:

• Cleavable linkers — designed to be cleaved by specific conditions in the tumor microenvironment or within cancer cells: acid-labile hydrazone linkers (cleaved at endosomal/lysosomal pH); protease-cleavable peptide linkers (cleaved by lysosomal cathepsins, e.g., Val-Cit-PABC in brentuximab vedotin); and disulfide linkers (cleaved by intracellular glutathione). Cleavable linkers enable the bystander effect when the released payload is cell-permeable.
• Non-cleavable linkers — stable in circulation and released only after complete antibody degradation in the lysosome, producing an amino acid-payload metabolite. These generate a more selective intracellular release mechanism with reduced bystander effect and potentially better tolerability.

3. The cytotoxic payload

The payload must be extraordinarily potent — because only a limited number of ADC molecules can be delivered to each cancer cell, the drug must kill at picomolar to low-nanomolar intracellular concentrations. ADC payloads are typically 100–1,000× more potent than conventional chemotherapeutic agents. The three major payload classes in clinical use are:

• Microtubule-disrupting agents — auristatins (MMAE, MMAF), maytansinoids (DM1, DM4), and taxanes. MMAE (monomethyl auristatin E) — used in brentuximab vedotin, polatuzumab vedotin, and enfortumab vedotin — inhibits tubulin polymerization, blocking mitosis and inducing apoptosis.
• DNA-damaging agents — calicheamicins (gemtuzumab ozogamicin, inotuzumab ozogamicin), duocarmycins (DNA alkylators), pyrrolobenzodiazepines (PBDs, DNA crosslinkers), and topoisomerase I inhibitors (DXd — used in trastuzumab deruxtecan and sacituzumab govitecan).
• Emerging payload classes — RNA polymerase inhibitors (α-amanitin), TLR agonists (for immunostimulatory ADCs), and PROTACs (bifunctional protein degraders), all under investigation as next-generation ADC payloads.

Mechanism of action of antibody drug conjugates

The mechanism of action of antibody drug conjugates follows a sequential intracellular delivery pathway — each step is critical to ADC efficacy, and failure at any step can reduce therapeutic activity.

Step 1: Target antigen binding

The ADC circulates in the bloodstream and binds selectively to the target tumor-associated antigen (TAA) overexpressed on cancer cell surfaces. Binding affinity (Kd typically in the low nanomolar range), antigen density on tumor cells, and shed antigen levels all influence the fraction of ADC that reaches tumor tissue. High circulating shed antigen can act as a sink, binding ADC before it reaches the tumor and reducing on-target delivery.

Step 2: Receptor-Mediated endocytosis

Upon antibody binding, the ADC-antigen complex is rapidly internalized into the cancer cell through receptor-mediated endocytosis — the antibody essentially hijacks the cell’s normal receptor recycling machinery. The rate and efficiency of internalization are major determinants of ADC potency. Targets that are rapidly and completely internalized (high internalization rate constant, minimal recycling back to the cell surface) are preferred. Internalization kinetics can be measured using flow cytometry with fluorescently labeled ADCs or confocal microscopy.

Step 3: Endosomal trafficking & lysosomal processing

The internalized endosome matures and acidifies as it traffics toward lysosomes. For cleavable ADCs, the acidic endosomal pH or lysosomal enzymes (primarily cathepsin B for Val-Cit peptide linkers) cleave the linker, releasing the payload. For non-cleavable ADCs, the antibody is fully degraded by lysosomal proteases, releasing an amino acid-payload metabolite (e.g., MMAF-Lys for MMAF-based ADCs) that retains cytotoxic activity inside the cell but cannot permeate into neighboring cells.

Step 4: Intracellular payload activity & apoptosis

Released payload exerts its cytotoxic mechanism: microtubule inhibitors (MMAE, DM1) bind tubulin and block mitotic spindle formation, arresting cell division and triggering apoptosis; topoisomerase I inhibitors (DXd) cause DNA strand breaks during replication; DNA crosslinkers (PBDs, calicheamicins) form interstrand DNA crosslinks. The intracellular payload concentration required for cell killing depends on the payload’s intrinsic potency — typically picomolar to low nanomolar IC50.

Step 5: Bystander effect

Cell-permeable payloads (such as MMAE and DXd) released from ADC-targeted antigen-positive cells can diffuse through the cell membrane into neighboring antigen-negative tumor cells — creating a bystander cytotoxic effect. This is particularly valuable for targeting heterogeneous solid tumors where antigen expression is not uniform across all tumor cells. Non-cell-permeable payloads (MMAF) have minimal bystander activity, providing a more restricted cytotoxic zone around antigen-expressing cells.

ADC Pharmacokinetics (PK)

The pharmacokinetics of antibody drug conjugates are fundamentally more complex than either conventional small-molecule drugs or unconjugated monoclonal antibodies. An ADC is not a single molecular entity — it is a dynamic mixture of species that evolves over time in circulation, each with distinct PK behavior.

Multi-Analyte PK assessment

Comprehensive ADC PK characterization requires simultaneous measurement of multiple analytes:

• Total antibody (TAb) — all antibody species regardless of conjugation status; measured by anti-idiotype ELISA; reflects overall antibody clearance
• Conjugated ADC — antibody species with at least one attached payload; measured by ELISA capturing payload-bearing antibody; the pharmacologically active species
• Average DAR in circulation — tracked over time by LC-MS/MS; typically decreases from nominal DAR as deconjugation occurs
• Free (unconjugated) payload — released payload in plasma; measured by LC-MS/MS; primary contributor to systemic toxicity

Key ADC PK parameters

ADC PK analysis generates parameters for each analyte, including:

• Maximum plasma concentration (Cmax) and area under the curve (AUC) for total antibody, conjugated ADC, and free payload
• Clearance (CL) and volume of distribution (Vd) for the antibody component
• Deconjugation rate constant (kdeconj) — the rate at which payload detaches from the antibody in plasma
• Free payload Cmax, AUC, and half-life — key safety PK parameters
• Tumor PK — intratumoral ADC and payload concentrations from preclinical xenograft studies

Target-Mediated drug disposition (TMDD)

Like unconjugated antibodies, ADCs can exhibit Target-Mediated Drug Disposition (TMDD) — where binding to the high-affinity, low-capacity target antigen contributes significantly to drug clearance at low dose levels. TMDD manifests as non-linear, dose-dependent PK: at low doses, target-mediated clearance dominates; at higher doses, the target is saturated and PK becomes more linear. Understanding TMDD is essential for ADC dose selection and for translating preclinical PK to human PK predictions. This connects directly to Excelra’s iQSP platform for mechanistic PK/PD modeling.

ADC PK/PD modeling

PK/PD modeling is indispensable in ADC development — characterizing the complex relationships between ADC dose, multi-analyte PK, tumor exposure, antitumor efficacy, and toxicity to support dose optimization, clinical trial design, and regulatory submissions.

Mechanistic ADC PK/PD models

Mechanistic ADC PK/PD models explicitly incorporate the biological processes governing ADC disposition and action:

• ADC distribution model — two-compartment model for total antibody PK with TMDD binding to the target antigen
• Deconjugation model — describes DAR-dependent deconjugation in plasma, generating free payload
• Tumor disposition model — antigen binding, internalization, lysosomal trafficking, and intracellular payload accumulation
• Efficacy model — links intracellular payload concentration to cell kill rate, tumor growth inhibition, and tumor regression
• Toxicity model — links free plasma payload (or off-target tissue exposure) to dose-limiting toxicity endpoints

Translational PK/PD for dose selection

One of the most critical applications of ADC PK/PD modeling is translating preclinical efficacy and safety data into first-in-human dose predictions. Species differences in FcRn-mediated antibody recycling, target antigen expression levels, and payload metabolism must all be accounted for. Allometric scaling combined with mechanistic TMDD models provides the most reliable framework for human PK prediction. Excelra’s clinical pharmacology and clinical data services team specializes in building and applying these models for ADC programs.

Population PK modeling for ADCs

Population PK (PopPK) modeling of ADC clinical data characterizes inter-patient variability in ADC PK and identifies covariates — such as body weight, baseline tumor burden, target antigen expression level, and albumin concentration — that influence ADC exposure. PopPK models support flat vs. weight-based dosing decisions, pediatric dose extrapolation, and exposure-response analyses for both efficacy (tumor response) and safety (adverse events).

Approved ADCs & clinical pipeline

The ADC field has accelerated dramatically in the past five years, with multiple blockbuster approvals and transformative clinical results reshaping oncology practice.

The approval of trastuzumab deruxtecan (T-DXd/Enhertu) represents a paradigm shift — extending ADC therapy to HER2-low breast cancer (IHC 1+ or 2+/ISH-negative), a population previously considered HER2-negative and ineligible for HER2-targeted therapy. This dramatically expanded the treatable population and demonstrated that ADCs can overcome the limitations of conventional antibody-based therapies by delivering highly potent payloads even to cells with low antigen expression.

ADC Applications in oncology

Antibody drug conjugates have achieved their most transformative clinical impact in oncology, where they address the fundamental challenge of delivering highly toxic agents selectively to tumor cells.

Breast cancer

ADCs have become standard of care in HER2-positive and triple-negative breast cancer. Trastuzumab deruxtecan has demonstrated superiority over chemotherapy in HER2-low breast cancer, effectively creating a new molecular subtype of the disease. Sacituzumab govitecan (TROP2-targeted) has shown significant activity in triple-negative breast cancer, a histotype historically lacking targeted therapy options. Multiple next-generation ADCs targeting HER3, B7-H4, and LIV-1 are in clinical development for breast cancer subtypes unaddressed by current agents.

Hematologic malignancies

ADCs were first developed and validated in hematologic cancers — where abundant surface antigen expression, good antibody penetration of accessible tumor cells, and defined patient populations enabled rapid clinical proof-of-concept. Brentuximab vedotin transformed the treatment of CD30+ lymphomas; inotuzumab ozogamicin and gemtuzumab ozogamicin (re-approved in 2017) address ALL and AML respectively. The highly potent PBD payload class (loncastuximab tesirine) has expanded treatment options for relapsed/refractory DLBCL.

Solid tumors beyond breast cancer

The success of ADCs in breast cancer has catalyzed their development across solid tumor types. Enfortumab vedotin (Nectin-4) combined with pembrolizumab has become a first-line standard of care in urothelial carcinoma. Trastuzumab deruxtecan is approved for HER2-mutant NSCLC and HER2-overexpressing gastric cancer. ADCs targeting TROP2, HER3, Mesothelin, CEACAM5, and Claudin 18.2 are in advanced clinical development for lung, colorectal, pancreatic, and ovarian cancers — diseases with very limited current targeted therapy options.

ADCs Beyond oncology

While oncology has dominated ADC development, the platform is increasingly being explored in non-oncology indications where targeted delivery of a potent effector molecule to specific cell types offers therapeutic advantages.

Autoimmune disease

Immunostimulatory ADCs (isADCs) — which deliver immune-activating payloads (TLR agonists, STING agonists) to tumor-infiltrating immune cells or immunosuppressive regulatory T cells — are an emerging modality bridging ADC and immuno-oncology. In autoimmune disease, ADCs targeting B cell antigens (CD19, CD20) with payloads that ablate autoreactive B cell populations are being investigated for refractory systemic lupus erythematosus and rheumatoid arthritis.

Infectious disease

ADCs targeting surface antigens on bacteria or virally infected cells represent early-stage research, with potential applications in antibiotic-resistant bacterial infections and HIV reservoir targeting. While significantly earlier in development than oncology ADCs, these programs illustrate the versatility of the ADC platform.

ADC Resistance mechanisms

Understanding and overcoming resistance is one of the central challenges in the clinical development of antibody drug conjugates. Resistance can be intrinsic (present at baseline) or acquired (emerging during treatment).

• Target antigen loss or downregulation — reduction in tumor cell surface antigen expression reduces ADC binding and payload delivery; the most common resistance mechanism
• Reduced internalization — decreased receptor-mediated endocytosis efficiency reduces intracellular payload delivery even with maintained surface expression
• Lysosomal dysfunction — impaired lysosomal proteolytic activity reduces linker cleavage and payload release for protease-cleavable ADCs
• Drug efflux pump upregulation — overexpression of MDR1/P-gp or ABCG2 pumps the released payload out of the cell, reducing intracellular concentration below the cytotoxic threshold
• Payload target resistance — mutations in tubulin (for microtubule-targeting payloads) or topoisomerase I (for DXd) reduce payload efficacy
• Apoptosis pathway defects — loss of pro-apoptotic regulators (BCL-2 family) can prevent cell death even when payload delivery is intact

Strategies to overcome ADC resistance include: combination with complementary targeted therapies or checkpoint inhibitors; alternative ADCs targeting different antigens on the same tumor; next-generation linker/payload designs that circumvent efflux pump resistance; and biomarker-driven patient selection to identify tumors most likely to respond.

Next-Generation ADC technologies

The ADC field is rapidly evolving beyond first-generation designs, with several technological innovations poised to expand therapeutic windows, overcome resistance, and address new disease areas.

Bispecific ADCs

Bispecific antibody-drug conjugates use bispecific antibodies to simultaneously bind two different tumor antigens, improving tumor selectivity, overcoming antigen heterogeneity, and potentially improving internalization efficiency. Multiple bispecific ADC platforms targeting antigen pairs (HER2 × HER3, HER2 × CD3, FRα × FOLH1) are in early clinical development.

Probody ADCs (Masked ADCs)

Probody ADCs use a protease-cleavable masking peptide on the antibody binding site that suppresses antigen binding in normal tissues (where the activating protease is inactive) but is cleaved and activated in the tumor microenvironment (where tumor-associated proteases such as uPA and matrix metalloproteases are highly active). This conditional activation strategy improves the selectivity of ADC target engagement and the therapeutic window for targets with normal tissue expression.

PROTAC-ADCs

Linking PROTACs (proteolysis-targeting chimeras) to antibodies creates PROTAC-ADCs — targeted degraders that can selectively deliver protein degradation activity to tumor cells. This emerging modality combines the selectivity of antibody targeting with the unique mechanism of targeted protein degradation, potentially addressing targets that are undruggable by conventional payload-based ADCs.

Challenges in ADC development

Therapeutic window & toxicity

Despite their targeted delivery mechanism, ADCs still cause significant systemic toxicity — primarily from off-target payload release in circulation or from ADC uptake by normal cells expressing low levels of the target antigen. Common dose-limiting toxicities include peripheral neuropathy (microtubule inhibitor payloads), thrombocytopenia (platelet uptake), neutropenia (bone marrow toxicity), and interstitial lung disease (ILD, particularly for T-DXd). Managing the therapeutic window through optimal DAR, linker stability, payload selection, and dose scheduling remains the central challenge of ADC development.

Manufacturing complexity

ADCs are among the most complex biopharmaceuticals to manufacture — requiring integrated production of the antibody, synthesis of the highly potent cytotoxic payload, controlled conjugation chemistry, and rigorous analytical characterization of the heterogeneous product mixture. The requirement to handle highly toxic payloads under strict containment conditions adds significant manufacturing cost and complexity. Site-specific conjugation technologies improve product homogeneity but introduce their own manufacturing challenges.

Regulatory & CMC considerations

The regulatory characterization of ADCs requires an extensive Chemistry, Manufacturing, and Controls (CMC) package covering the antibody intermediate, the small molecule payload-linker, the conjugation process, and the final ADC product — including full DAR distribution characterization, aggregation testing, and stability data. The complexity of ADC analytical characterization relative to conventional biologics or small molecules requires specialized regulatory strategy and specialized bioanalytical methods.

How Excelra supports ADC programs

Excelra provides specialized data, analytical, and modeling capabilities to support ADC drug discovery and development — from target identification through clinical PK/PD analysis and regulatory submission support.

• ADC PK Dataset Curation & Analysis — systematic curation of ADC clinical pharmacology datasets from published literature and clinical study reports; extraction of multi-analyte PK parameters (total antibody, conjugated ADC, free payload) across approved and investigational ADCs. See Excelra’s clinical data services.
• ADC PK/PD Modeling & Simulation — mechanistic and empirical PK/PD models for ADC programs; TMDD modeling; deconjugation kinetic modeling; tumor growth inhibition models; population PK analysis; and dose optimization for clinical trial design. Powered by Excelra’s iQSP Quantitative Systems Pharmacology platform.
• Biomarker & Target Assessment — target antigen expression profiling, internalization kinetics data curation, and biomarker-driven patient stratification support for ADC clinical development. Connects to Excelra’s biomarker discovery capabilities.
• Literature-Derived ADC Datasets — curated, analysis-ready ADC PK, efficacy, and safety datasets extracted from published literature and clinical study reports — structured for immediate use in modeling, benchmarking, and regulatory submissions.
• Clinical Pharmacology Data Integration — integration of ADC PK/PD data with genomic biomarker data, RWE, and clinical outcomes using Excelra’s data services and FAIR data frameworks.

Conclusion

Antibody Drug Conjugates have fulfilled the original promise of targeted cancer therapy — delivering the cell-killing potency of chemotherapy with the selectivity of a monoclonal antibody. From the early struggles of first-generation ADCs to the transformative clinical results of trastuzumab deruxtecan and sacituzumab govitecan, the field has matured into one of the most productive and commercially significant platforms in modern oncology drug discovery.

The pharmacological complexity of ADCs — multi-component structure, dynamic PK, DAR heterogeneity, TMDD, and bystander effects — demands sophisticated analytical and modeling approaches that go beyond conventional drug development frameworks. ADC PK/PD modeling, multi-analyte bioanalytical strategies, and mechanistic translational modeling are no longer optional specialties but core competencies for any serious ADC development program.

Looking ahead, the next generation of ADCs — bispecific, masked, site-specifically conjugated, and PROTAC-armed — will address the limitations of current agents and expand the patient populations that can benefit from this remarkable drug class. As the ADC field extends beyond oncology into autoimmune disease and infectious disease, the need for specialized data infrastructure, curated clinical pharmacology datasets, and expert PK/PD modeling will only grow.

Excelra’s integrated capabilities in ADC clinical pharmacology data curation, PK/PD modeling, and biomarker analytics provide pharmaceutical and biotech teams with the data and modeling foundation needed to accelerate ADC programs efficiently and confidently.

Explore Excelra’s Clinical Pharmacology Data Services →